1. Equivalent Outcome of Autologous Stem Cell Transplantation and Reduced Intensity Conditioning Stem Cell Transplantation in Acute Myeloid Leukemia Patients with t(8;21).
- Author
-
Eom, Ki-Seong, Kim, Hee-Je, Cho, Byung-Sik, Lee, Sung Eun, Yahng, Seung-ah, Yoon, Jae-Ho, Shin, Seung-Hwan, Jeon, Young-Woo, Kim, Jung-Ho, Kim, Yoo-Jin, Lee, Seok, Min, Chang-Ki, Cho, Seok-Goo, Kim, Dong-Wook, Lee, Jong-Wook, Min, Woo-Sung, and Park, Chong-Won
- Subjects
- *
STEM cell transplantation , *TREATMENT effectiveness , *ACUTE myeloid leukemia treatment , *LEUKEMIA complications , *CANCER relapse , *CANCER patients , *MEDICAL statistics - Abstract
We analyzed the outcome of stem cell transplantation (SCT) for 59 acute myeloid leukemia (AML) patients with t(8;21). The 5-year overall and disease-free survival (OS and DFS) were 70.2 and 68.4%, respectively. The 5-year cumulative incidence of relapse (CIR) and nonrelapse mortality were 16.9 and 13.6%, respectively. OS and DFS in the reduced-intensity conditioning (RIC)-SCT group (70.4%) were not different from in the autologous SCT (ASCT) group (72.4 and 69.0%, respectively). Age was a factor affecting OS (p = 0.007) and DFS (p = 0.008) in the ASCT group, but not in the RIC-SCT group. In the ASCT group, lack of the X chromosome (-X) and an age of >50 years were associated with inferior survival; however, these differences disappeared in the RIC-SCT group. CIR was significantly higher in patients with -X than in those without -X only in the ASCT group (p = 0.038), i.e. not in the RIC-SCT group. ASCT and RIC-SCT are equally effective for the intensification of postremission treatment of AML patients with t(8;21). The subgroups with advanced age or -X should be preferentially considered for RIC-SCT, rather than ASCT. Further investigations with randomized prospective trials of a sizeable study population are warranted. © 2014 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF